OraSure Technologies Inc. (OSUR) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 80% of 52W Range • RSI-14 at 52 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±10.6% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While OSUR currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.76) and Max Pain ($4.28) forces dealer call-delta covering toward $4.81.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
OraSure Technologies Inc. (OSUR) slipped -0.49% to $4.08, trading at 80% of its 52-week range ($2.08 – $4.58). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
BETHLEHEM, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its third quarter 2026 financial results on Monday, November 9, 2026, after the market close
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -38.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OSUR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OSUR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, OraSure Technologies Inc. (OSUR) ranks #892 by composite RQD confidence (32/100, grade E) and #527 by equity capitalization ($281.4M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while INFU leads on capital efficiency and profitability with 12.8% ROIC and 56.0% gross margin. INFU currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with OSUR at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OSUR
ACTIVE
OraSure Technologies Inc. | E | 32/100 | — | 41.9% | -35.0% | -0.49% | $281.4M | Benchmark Subject |
| INFU InfuSystems Holdings Inc. | B+ | 76/100 | 43.4x | 56.0% | 12.8% | +0.91% | $287.8M | /infu-vs-osur → |
| ANIK Anika Therapeutics Inc. | D+ | 55/100 | — | 56.6% | -10.2% | +1.11% | $291.6M | /anik-vs-osur → |
| TMCI Treace Medical Concepts Inc. | D- | 41/100 | — | 79.8% | -32.4% | +4.76% | $329.1M | /tmci-vs-osur → |
| CLPT ClearPoint Neuro Inc. | E | 34/100 | — | 61.4% | -35.0% | +1.23% | $342.7M | /clpt-vs-osur → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), OraSure Technologies Inc. (OSUR) reported GAAP revenue of $115.0M (-38.1% vs. FY2024 revenue of $185.8M , and -71.6% cumulative change since FY2023) , GAAP net income of -$68.7M, operating cash flow of -$49.0M, and free cash flow of -$53.2M (-325.7% YoY). On the balance sheet, OSUR closed FY2025 with $403.2M in total assets against $0 in total debt (Altman Z-Score: 2.47, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $115.0M | -$68.7M | -$49.0M | -$53.2M | $403.2M | — |
| FY2024 (FY) | 2024-12-31 | $185.8M | -$19.5M | $27.4M | $23.6M | $479.7M | — |
| FY2023 (FY) | 2023-12-31 | $405.5M | $53.7M | $141.6M | $141.6M | — | — |
As of 2026-11-01, OraSure Technologies Inc. (NASDAQ: OSUR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.08 (-0.49% 1D, market cap $281.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 4/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OSUR ranks #892 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), OSUR carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 41.9%, and ROIC of -35.0%. By comparison, INFU (InfuSystems Holdings Inc.) holds a B+ grade (76/100 RQD, P/E 43.4x, ROIC 12.8%, cap $287.8M) and ANIK (Anika Therapeutics Inc.) posts a D+ grade (55/100 RQD, P/E N/A, ROIC -10.2%, cap $291.6M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).
Per OSUR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001116463), OraSure Technologies Inc. generated $115.0M in revenue (-38.1% YoY), -$68.7M in net income, and -$53.2M in free cash flow against $403.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
OSUR last traded at $4.08 (-0.49% on volume of 1,232,986 shares), positioning the stock +8.51% above its 50-day simple moving average ($3.76) and +16.24% above its 200-day simple moving average ($3.51). Across its 52-week range of $2.08 to $4.58, OSUR sits at the 80.0% percentile with a 14-day RSI of 52.0 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($3.65 to $4.51).
Why OSUR Stock slipped -0.49% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.